Skip to main content

Septic Shock

15
Pipeline Programs
26
Companies
40
Clinical Trials
8 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
9
2
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
267%
Monoclonal Antibody
133%
+ 43 programs with unclassified modality

Competitive Landscape

25 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
7 programs
1
norepinephrine+vasopressinPhase 41 trial
4% gelatinN/A1 trial
Critical Closing Pressure and PCO₂ Gap in Fluid Resuscitation for Septic ShockN/A1 trial
Dexmedetomidine HydrochlorideN/A
ResuscitationN/A1 trial
+2 more programs
Active Trials
NCT04515511Unknown50Est. Sep 2022
NCT07043192Active Not Recruiting60Est. Feb 2026
NCT02566460Completed360
+3 more trials
Biocorp
BiocorpFrance - Issoire
3 programs
2
1
VBI-SPhase 31 trial
LB1148Phase 21 trial
VBI-SPhase 21 trial
Active Trials
NCT02317549Terminated8Est. Mar 2016
NCT04257136Unknown20Est. Dec 2023
NCT06072430Recruiting46Est. Dec 2025
Vivacelle Bio
Vivacelle BioIL - Chicago
2 programs
1
1
VBI-SPhase 3
VBI-SPhase 2
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
Hydrocortisone, sodium succinatePhase 31 trial
Active Trials
NCT03401398Recruiting500Est. Dec 2026
Innovation Pharmaceuticals
1 program
1
IloprostPhase 2/31 trial
Active Trials
NCT04123444Completed279Est. Jun 2022
Lundbeck
LundbeckDenmark - Copenhagen
1 program
1
Mild Induced HypothermiaPhase 2/31 trial
Active Trials
NCT01455116Terminated433Est. Nov 2016
Baxter
BaxterCosta Rica - Cartago
3 programs
3
5% albuminPhase 2
EsmololPhase 2Small Molecule
Esmolol administrationPhase 2
Artcline
ArtclineGermany - Rostock
1 program
1
ARTICEPhase 22 trials
Active Trials
NCT07388628Recruiting200Est. Dec 2027
NCT05442710Recruiting142Est. Jun 2026
Palisade Bio
Palisade BioCARLSBAD, CA
1 program
1
LB1148Phase 2
Adrenomed
AdrenomedGermany - Hennigsdorf
1 program
1
adrecizumabPhase 2Monoclonal Antibody3 trials
Active Trials
NCT03085758Completed301Est. Dec 2019
NCT03083171Completed24Est. May 2017
NCT02991508Completed24Est. Sep 2016
CytoSorbents
CytoSorbentsPRINCETON, NJ
4 programs
CytoSorbN/A1 trial
CytoSorb-TherapyN/A1 trial
Cytokine AdsorptionN/A1 trial
Cytosorb® 300 mlN/A1 trial
Active Trials
NCT05146336Recruiting3,000Est. Sep 2032
NCT04013269Unknown32Est. Dec 2023
NCT04910893Completed48Est. Dec 2018
+1 more trials
Baxter International
3 programs
5% albuminPHASE_21 trial
EsmololPHASE_2Small Molecule1 trial
Esmolol administrationPHASE_21 trial
Active Trials
NCT00819416Completed47Est. Feb 2010
NCT02068287Unknown25Est. Jun 2017
NCT02120404Unknown45Est. Oct 2023
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
3 programs
FE 202158PHASE_21 trial
FE 202158 1.25PHASE_21 trial
selepressinPHASE_2_31 trial
Active Trials
NCT01612676Completed31Est. Nov 2013
NCT01000649Completed53Est. Sep 2011
NCT02508649Terminated868Est. Feb 2018
Eppendorf
EppendorfGermany - Hamburg
2 programs
CytoSorb-TherapyN/A
Examination of ADMA Serum Level and DDAH IIN/A1 trial
Active Trials
NCT01632059Completed120Est. Apr 2017
Grifols
GrifolsNEW YORK, NY
2 programs
Effects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic ShockN/A1 trial
Albutein® 200 g/L or Plasbumin® 20PHASE_31 trial
Active Trials
NCT05094856Completed61Est. Mar 2023
NCT03869385Terminated440Est. Jun 2023
Octapharma
OctapharmaAustria - Vienna
2 programs
OctaplasLGPHASE_21 trial
OctaplasLG®PHASE_41 trial
Active Trials
NCT03092245Completed44Est. Apr 2019
NCT02875236Terminated5Est. Nov 2016
Defence Therapeutics
Defence TherapeuticsBC - Vancouver
1 program
Angiotensin IIN/A1 trial
Active Trials
NCT06234592Recruiting45Est. Jul 2026
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Life After Pediatric Sepsis EvaluationN/A1 trial
Active Trials
NCT01415180Completed389Est. Jun 2018
Mott
MottCT - Farmington
1 program
Life After Pediatric Sepsis EvaluationN/A
Autonomous Therapeutics
1 program
Methylene BlueN/A1 trial
Active Trials
NCT06481410Recruiting488Est. Jun 2026
Shield Therapeutics
Shield TherapeuticsMA - Wellesley
1 program
Near-infrared spectroscopy assessmentN/A1 trial
Active Trials
NCT01062685Completed186Est. Jan 2010
Vantive
VantiveIL - Deerfield
1 program
Oxiris FilterN/A1 trial
Active Trials
NCT07334327Not Yet Recruiting62Est. Dec 2027
MSD
MSDIreland - Ballydine
1 program
Septic shockN/A1 trial
Active Trials
NCT04080453Completed202Est. Apr 2024
ExThera Medical
ExThera MedicalCA - Martinez
1 program
Seraph-100 + State of the Art CareN/A1 trial
Active Trials
NCT05011656Active Not Recruiting15Est. Jul 2027
Precision BioSciences
1 program
Early VasopressinPHASE_31 trial
Active Trials
NCT06464510Recruiting2,800Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
UNION therapeuticsnorepinephrine+vasopressin
OctapharmaOctaplasLG®
Precision BioSciencesEarly Vasopressin
BiocorpVBI-S
GrifolsAlbutein® 200 g/L or Plasbumin® 20
Human BioSciencesHydrocortisone, sodium succinate
Innovation PharmaceuticalsIloprost
Ferring Pharmaceuticalsselepressin
LundbeckMild Induced Hypothermia
ArtclineARTICE
BiocorpVBI-S
Adrenomedadrecizumab
OctapharmaOctaplasLG
Baxter InternationalEsmolol administration
BiocorpLB1148

Showing 15 of 40 trials with date data

Clinical Trials (40)

Total enrollment: 13,073 patients across 40 trials

NCT05886192UNION therapeuticsnorepinephrine+vasopressin

The Construction and Application of Therapeutic System of Intelligent Decision-Oriented Hemodynamic Organized Therapy for Shock Patients

Start: May 2023Est. completion: Sep 202560 patients
Phase 4Unknown

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)

Start: Sep 2016Est. completion: Nov 20165 patients
Phase 4Terminated

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

Start: Nov 2024Est. completion: Sep 20272,800 patients
Phase 3Recruiting

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

Start: Aug 2024Est. completion: Dec 202546 patients
Phase 3Recruiting
NCT03869385GrifolsAlbutein® 200 g/L or Plasbumin® 20

Albumin Replacement Therapy in Septic Shock

Start: Oct 2019Est. completion: Jun 2023440 patients
Phase 3Terminated
NCT03401398Human BioSciencesHydrocortisone, sodium succinate

Stress Hydrocortisone In Pediatric Septic Shock

Start: Mar 2019Est. completion: Dec 2026500 patients
Phase 3Recruiting

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure

Start: Oct 2019Est. completion: Jun 2022279 patients
Phase 2/3Completed

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Start: Jul 2015Est. completion: Feb 2018868 patients
Phase 2/3Terminated
NCT01455116LundbeckMild Induced Hypothermia

The Cooling And Surviving Septic Shock Study (CASS)

Start: Nov 2011Est. completion: Nov 2016433 patients
Phase 2/3Terminated

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Start: Jul 2022Est. completion: Jun 2026142 patients
Phase 2Recruiting

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

Start: Feb 2020Est. completion: Dec 202320 patients
Phase 2Unknown

Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB

Start: Dec 2017Est. completion: Dec 2019301 patients
Phase 2Completed

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial

Start: Apr 2017Est. completion: Apr 201944 patients
Phase 2Completed
NCT02120404Baxter InternationalEsmolol administration

Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock

Start: Apr 2015Est. completion: Oct 202345 patients
Phase 2Unknown

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

Start: Apr 2015Est. completion: Mar 20168 patients
Phase 2Terminated

Esmolol Effects on Heart and Inflammation in Septic Shock

Start: Dec 2013Est. completion: Jun 201725 patients
Phase 2Unknown

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

Start: Jun 2012Est. completion: Nov 201331 patients
Phase 2Completed

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

Start: Nov 2009Est. completion: Sep 201153 patients
Phase 2Completed

Fluid Resuscitation in Early Septic Shock

Start: Feb 2009Est. completion: Feb 201047 patients
Phase 2Completed

Adrecizumab-LPS Study

Start: Jan 2017Est. completion: May 201724 patients
Phase 1Completed

Adrecizumab Phase 1 Trial

Start: May 2016Est. completion: Sep 201624 patients
Phase 1Completed
NCT07334327VantiveOxiris Filter

Extracorporeal Blood Purification Using Oxiris for Septic Shock (EXPLORE Study)

Start: Feb 2026Est. completion: Dec 202762 patients
N/ANot Yet Recruiting

ARTICE® Real Data Collection & Observational Trial, Phase 4 Study

Start: Sep 2025Est. completion: Dec 2027200 patients
N/ARecruiting
NCT07043192UNION therapeuticsCritical Closing Pressure and PCO₂ Gap in Fluid Resuscitation for Septic Shock

Critical Closing Pressure and PCO₂ Gap in Fluid Resuscitation for Septic Shock

Start: Apr 2025Est. completion: Feb 202660 patients
N/AActive Not Recruiting

Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock

Start: Jun 2024Est. completion: Jun 2026488 patients
N/ARecruiting
NCT05011656ExThera MedicalSeraph-100 + State of the Art Care

Blood Purification for the Treatment of Pathogen Associated Shock

Start: Apr 2024Est. completion: Jul 202715 patients
N/AActive Not Recruiting

The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock

Start: Jan 2024Est. completion: Jul 202645 patients
N/ARecruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

Start: Jun 2022Est. completion: Sep 20323,000 patients
N/ARecruiting
NCT05094856GrifolsEffects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Shock

Effects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Shock

Start: Feb 2022Est. completion: Mar 202361 patients
N/ACompleted
NCT04963920CytoSorbentsCytosorb® 300 ml

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

Start: Jan 2022Est. completion: May 2027260 patients
N/ASuspended
NCT04080453MSDSeptic shock

Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock.

Start: Nov 2020Est. completion: Apr 2024202 patients
N/ACompleted
NCT04013269CytoSorbentsCytoSorb-Therapy

Adjuvant Therapy With CytoSorb in Refractory Septic Shock

Start: Jan 2020Est. completion: Dec 202332 patients
N/AUnknown

Whether a Minimal Volume Could Predict Fluid Responsiveness Using Thermodilution by PAC in Septic Shock Patients

Start: Jul 2019Est. completion: Sep 202250 patients
N/AUnknown
NCT04910893CytoSorbentsCytokine Adsorption

Cytokine Adsorption in Severe, Refractory Septic Shock

Start: Nov 2014Est. completion: Dec 201848 patients
N/ACompleted
NCT01877798UNION therapeuticsvolume resuscitation, vasoactive drug

Venoarterial PCO2 Difference /Arteriovenous O2 Content Difference Ratio as Goal of Early Septic Shock Therapy

Start: Jun 2013300 patients
N/AUnknown
NCT01415180Angeles TherapeuticsLife After Pediatric Sepsis Evaluation

Life After Pediatric Sepsis Evaluation

Start: Jun 2013Est. completion: Jun 2018389 patients
N/ACompleted

The Effect of Lactate Clearance Oriented Haemodynamic Therapy on the Outcome of Patients With Septic Shock

Start: Jan 2013360 patients
N/ACompleted

Continuos Terlipressin Infusion in Septic Shock

Start: Jan 2013Est. completion: Jan 20161,000 patients
N/AUnknown
NCT01632059EppendorfExamination of ADMA Serum Level and DDAH II

Examination of ADMA Serum Level and DDAH II

Start: Feb 2012Est. completion: Apr 2017120 patients
N/ACompleted
NCT01062685Shield TherapeuticsNear-infrared spectroscopy assessment

Near Infrared Spectroscopy (St02)

Start: Jan 2009Est. completion: Jan 2010186 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
8 actively recruiting trials targeting 13,073 patients
26 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.